| Literature DB >> 35801132 |
Cuihua Wang1, Jun Xing1, Baoli Zhao1, Yahui Wang1, Lizhuang Zhang1, Yebo Wang1, Mingqi Zheng2, Gang Liu2.
Abstract
Objective: The purpose of this study is to compare the effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on exercise capacity and several prognostic markers in patients with coronary artery disease (CAD) and heart failure (HF).Entities:
Mesh:
Year: 2022 PMID: 35801132 PMCID: PMC9203221 DOI: 10.1155/2022/4273809
Source DB: PubMed Journal: Cardiovasc Ther ISSN: 1755-5914 Impact factor: 3.368
Database and search terms.
| Database | Search terms | |
|---|---|---|
| PubMed | Search ((((“High-Intensity Interval Training”[Mesh]) OR ((((((((((((High Intensity Interval Training[Title/Abstract]) OR High-Intensity Interval Trainings[Title/Abstract]) OR Interval Training, High-Intensity [Title/ Abstract]) OR Interval Trainings, High-Intensity[Title/Abstract]) OR Training, High-Intensity Interval [Title/Abstract]) OR Trainings, High- | |
| Embase | Session results | |
| No. query results | Result date | |
| #24. #1 AND #10 AND #23 | 1 3 Dec 2019 | |
| #23. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR | 2,178 3 Dec 2019 | |
| #18 OR #19 OR #20 OR #21 OR #22 | ||
| #22. ‘sprint interval trainings':ti,ab | 1 3 Dec 2019 | |
| #21. ‘sprint interval training':ti,ab | 250 3 Dec 2019 | |
| #20. ‘high-intensity intermittent exercises':ti,ab | 12 3 Dec 2019 | |
| #19. ‘exercises, high-intensity intermittent':ti,ab | 3 Dec 2019 | |
| #18. ‘exercise, high-intensity intermittent':ti,ab | 2 3 Dec 2019 | |
| #17. ‘high-intensity intermittent exercise':ti,ab | 242 3 Dec 2019 | |
| #16. ‘trainings, high-intensity interval':ti,ab | 3 Dec 2019 | |
| #15. ‘training, high-intensity interval':ti,ab | 11 3 Dec 2019 | |
| #14. ‘interval trainings, high-intensity':ti,ab | 3 Dec 2019 | |
| #13. ‘interval training, high-intensity':ti,ab | 1 3 Dec 2019 | |
| #12. ‘high-intensity interval trainings':ti,ab | 3 3 Dec 2019 | |
| #11. ‘high intensity interval training'/exp | 1,831 3 Dec 2019 | |
| #10. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 | 11,281 3 Dec 2019 | |
| #9. ‘rehabilitations, cardiovascular':ti,ab | 3 Dec 2019 | |
| #8. ‘rehabilitation, cardiovascular':ti,ab | 8 3 Dec 2019 | |
| #7. ‘cardiovascular rehabilitations':ti,ab | 3 Dec 2019 | |
| #6. ‘cardiovascular rehabilitation':ti,ab | 511 3 Dec 2019 | |
| #5. ‘rehabilitations, cardiac':ti,ab | 3 Dec 2019 | |
| #4. ‘rehabilitation, cardiac':ti,ab | 37 3 Dec 2019 | |
| #3. ‘cardiac rehabilitations':ti,ab | 10 3 Dec 2019 | |
| #2. ‘heart rehabilitation'/exp | 10,958 3 Dec 2019 | |
| #1. ‘'random':ab,ti OR ‘placebo':ab,ti OR | 658,790 3 Dec 2019 | |
| ‘'double-blind':ab,ti | ||
| Cochrane | Search name: Cochrane-OA | |
| Web of Science | #1 TS=(Cardiac Rehabilitation OR Cardiac Rehabilitation∗ OR Rehabilitation, Cardiac OR Rehabilitation∗, Cardiac OR Cardiovascular Rehabilitation OR Cardiovascular Rehabilitation∗ OR Rehabilitation, Cardiovascular OR Rehabilitation∗, Cardiovascular) | |
| ClinicalTrials | Search “High-Intensity Interval Training” AND “Cardiac Rehabilitations” | |
| Wanfang Database | “心脏康复”和“高强度间歇训练” | |
| China National Knowledge Internet | “心脏康复”和“高强度间歇训练” | |
| CBM | “心脏康复”和“高强度间歇训练” | |
Figure 1Systematic review process. CAD: coronary artery disease; HF: heart failure.
General characteristics of each study included in the meta-analysis.
| Study, year | Disease | HIIT | MICT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample size | Gender | Age (years) | BMI (kg m−2) | LVEF (%) | Sample size | Gender | Age (years) | BMI (kg m−2) | LVEF (%) | ||
| Benda 2015 [ | HF | 10 | 9 M; 1 F | 63 ± 8 | 28.1 ± 7.5 | 37 ± 6 | 10 | 10 M | 64 ± 8 | 28.9 ± 4.7 | 38 ± 6 |
| Besnier 2019 [ | HF | 16 | 11 M; 5 F | 59 ± 13 | 25 ± 5 | 36 ± 8 | 15 | 14 M; 4 F | 59.5 ± 12 | 28 ± 5 | 36 ± 7 |
| Cardozo 2015 [ | CAD | 23 | 14 M; 9 F | 56 ± 12 | 27.5 ± 5.9 | 60 ± 14 | 24 | 16 M; 8 F | 62 ± 12 | 26.8 ± 4.8 | 63 ± 12 |
| Currie 2013 [ | CAD | 11 | NA | 62 ± 11 | 27.9 ± 4.9 | NA | 11 | NA | 68 ± 8 | 27.3 ± 4.2 | NA |
| Currie 2015 [ | CAD | 9 | 9 M | 63 ± 8 | 28.9 ± 4.8 | NA | 10 | 9 M; 1 F | 66 ± 8 | 27.3 ± 4.0 | NA |
| Ellingsen 2017 [ | HF | 77 | 63 M; 14 F | 65 ± 22.4 | 27.6 ± 5.4 | 29 ± 11.19 | 65 | 53 M; 12 F | 60 ± 14.4 | 27.5 ± 6.4 | 29 ± 12.4 |
| Freyssin 2012 [ | HF | 12 | 6 M; 6 F | 54 ± 9 | 24.8 ± 4.0 | 27.8 ± 4.7 | 14 | 7 M; 7 F | 55 ± 12 | 24.1 ± 5.4 | 30.7 ± 7.8 |
| Hornikx 2019 [ | HF | 10 | 5 M; 5 F | 64 ± 8 | 26 ± 4 | 30 ± 14 | 10 | 6 M; 4 F | 58 ± 11 | 29 ± 4 | 31 ± 14 |
| Jaureguizar 2016 [ | CAD | 36 | 28 M; 8 F | 58 ± 11 | 29.6 ± 4.6 | 62 ± 11 | 36 | 33 M; 3 F | 58 ± 11 | 29.5 ± 4.1 | 59 ± 14 |
| Koufaki 2014 [ | HF | 16 | 14 M; 2 F | 59.8 ± 7.4 | 28.9 ± 4.7 | 41.7 ± 10.3 | 17 | 13 M; 4 F | 59.7 ± 10.8 | 29.5 ± 4.7 | 35.2 ± 6.4 |
| Rognmo 2004 [ | CAD | 8 | 6 M; 2 F | 62.9 ± 11.2 | 26.7 ± 4.1 | 54.8 ± 9.1 | 9 | 8 M; 1 F | 61.2 ± 7.3 | 26.9 ± 2.7 | 51.9 ± 9.6 |
| Villelabeitia 2017 [ | CAD | 37 | 29 M; 8 F | 58 ± 11 | 29.6 ± 4.4 | 62 ± 11 | 36 | 33 M; 3 F | 58 ± 11 | 29.5 ± 4.1 | 59 ± 14 |
| Villelabeitia 2019 [ | CAD | 57 | 50 M; 7 F | 57.6 ± 9.8 | 29.1 ± 3.9 | 61.2 ± 10.1 | 53 | 42 M; 11 F | 58.3 ± 9.5 | 27.8 ± 3.7 | 60.3 ± 9.7 |
| Warburton 2005 [ | CAD | 7 | NA | 55 ± 7 | NA | NA | 7 | NA | 57 ± 8 | NA | NA |
| Wisløff 2007 [ | HF | 9 | 7 M; 2 F | 76.5 ± 9 | 24.5 ± 3 | 28.0 ± 7.3 | 9 | 7 M; 2 F | 74.4 ± 12 | 24.7 ± 3 | 32.8 ± 4.8 |
Characteristics for HIIT and MICT interventions.
| Study | Duration (weeks) | Exercise modality | HIIT | MICT | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exercise intensity (%max) (interval: rest) | Frequency (days/week) | Exercise time per week (min) | Attendance rate, dropouts and adverse events | Exercise intensity (%max) (interval: rest) | Frequency (days/week) | Exercise time per week (min) | Attendance rate, dropouts and adverse events | |||
| Benda | 12 | Cycle | 10 × 1 min90% | 2 | 70 | Attendance NR; dropouts = 2 | 60-75% | 2 | 60 | Attendance NR; dropouts = 2 (16%); adverse: NR |
| Besnier | 3.5 | Cycle | 80% PPO | 5 | 150 | Attendance = 94%; dropouts = 1; adverse = 0 | 60% PPO | 5 | 150 | Attendance: 100% |
| Cardozo | 16 | Running | 2 min 90% HRmax: | 3 | 120 | Attendance: NR; dropouts: NR; adverse = 0 | 70-75%HRmax | 3 | 120 | Attendance: NR; dropouts: NR; adverse = 0 |
| Currie | 12 | Cycle | 2 × 8 min100% PPO | 2 | 80 | Attendance: NR; dropouts: NR | 58% PPO | 2 | 80-100 | Attendance: NR; dropouts: NR; adverse = 0 |
| Currie | 24 | Cycle | 121% PPO | 2 | 120 | Attendance: NR; dropouts = 1 | 78% PPO | 2 | 120 | Attendance: NR |
| Ellingsen | 12 | Running or cycle | 4 × 4 min 90-95%HRmax; 3 min 60-70% HRmax | NR | NR | Attendance = 94%; dropouts = 1; adverse = 2 | 60-70%HRmax | NR | NR | Attendance = 94%; dropouts = 3; adverse = 4 |
| Freyssin | 8 | Running or cycle | 80% maximal power | 5 | 168 | Attendance = 100%; dropouts = 0; adverse = 0 | 50% maximal power | 5 | 360 | Attendance = 100%; dropouts = 0; adverse = 0 |
| Hornikx | 12 | Running or cycle | 5 × 3 min 80% Wpeak; 4 × 3 min 40% Wpeak | 3 | 99 | Attendance: NR; dropouts = 1 (10%); adverse = 1 (10%) | 50%Wpeak | 3 | 180 | Attendance: NR; dropouts = 1 (10%); adverse = 3 (33%) |
| Jaureguizar | 8 | Cycle | 105-135% VO2peak | 3 | 120 | Attendance = 92%; dropouts = 0; adverse = 0 | 65-70% VO2peak | 3 | 120 | Attendance = 87.5%; dropouts = 0; adverse = 0 |
| Koufaki | 24 | Cycle | 100% VO2peak | 3 | 120 | Attendance = 94%; dropouts = 1 (6%); adverse = 1 (6%) | 40-60% | 3 | 120 | Attendance = 100%; dropouts = 3; adverse = 3 |
| Rognmo | 10 | Running | 4 × 4 min 80-90% VO2peak; 50-60% VO2peak | 3 | 99 | Attendance = 77% | 50-60% | 3 | 123 | Attendance = 90%; dropouts = 1; adverse = 0 |
| Villelabeitia | 8 | Cycle | 105-135% VO2peak | 3 | 120 | Attendance = 92%; dropouts = 0; adverse = 0 | 65-70% | 3 | 120 | Attendance = 87.5%; dropouts = 0; adverse = 0 |
| Villelabeitia | 8 | Cycle | 108-126% VO2peak | 3 | 120 | Attendance = NR; dropouts = 0; adverse = 0 | 60-70% | 3 | 120 | Attendance = NR |
| Warburton | 16 | Running or climb stairs | 90% heart rate/VO2 reserve | 2 | 60 | Attendance: NR; dropouts = 0; adverse: NR | 65% heart rate/VO2 | 2 | 60 | Attendance: NR; dropouts = 0; adverse: NR |
| Wisløff | 12 | Running | 4 × 4 min 90-95% VO2peak; | 3 | 114 | Attendance = 92%; dropouts = 0; adverse = 0 | 70-75% | 3 | 141 | Attendance = 95%; dropouts = 1; adverse = 0 |
HIIT: high-intensity interval training; MICT: moderate-intensity continuous training; PPO: peak power output; HRmax: maximal heart rate; Wpeak: peak workload; VO2peak: peak oxygen uptake; NR: not reported.
Figure 2Risk of bias assessment.
Figure 3Forest plots of the effect of HIIT and MICT on peak VO2 for patients with CAD and HF. HIIT: high-intensity interval training; MICT: moderate-intensity continuous training; peak VO2: peak oxygen consumption; CAD: coronary artery disease; HF: heart failure; SD: standard deviation; CI: confidence interval.
Figure 4(a) Subgroup analysis of HIIT and MICT on peak VO2 according to disease categories (CAD versus HF); (b) sensitivity analysis. HIIT: high-intensity interval training; MICT: moderate-intensity continuous training; peak VO2: peak oxygen consumption; CAD: coronary artery disease; HF: heart failure; SD: standard deviation; CI: confidence interval.
Figure 5Subgroup analysis of HIIT and MICT on peak VO2 according to training duration (≤8weeks, 8-12weeks, and ≥12weeks). HIIT: high-intensity interval training; MICT: moderate-intensity continuous training; peak VO2: peak oxygen consumption; CAD: coronary artery disease; HF: heart failure; SD: standard deviation; CI: confidence interval.
Figure 6Forest plot summary of the effect of HIIT and MICT on prognostic markers in patients with CAD and HF: (a) anaerobic threshold (AT); (b) left ventricular ejection fraction (LVEF); (c) the VE/carbon dioxide production (VCO2) slope (the VE/VCO2slope); (d) the prognostic value of percent predicted VO2max (the predicted VO2 peak (%)). HIIT: high-intensity interval training; MICT: moderate-intensity continuous training; CAD: coronary artery disease; HF: heart failure; SD: standard deviation; CI: confidence interval.